FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Tepotinib granted Priority Review and is being evaluated under FDA Real-Time Oncology Review (RTOR) pilot program
Tepotinib is a highly targeted inhibitor of c-MET that is administered as a once-daily oral tablet
Data show robust, consistent and dura... Biopharmaceuticals, Oncology, FDA EMD Serono, Merck KGaA, Tepotinib, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Merck | New Drug Applications | Non-Small Cell Lung Cancer | Pharmaceuticals